Vaginal Cancer - Pipeline Review, H1 2016


#739373

72pages

Global Markets Direct

$ 2000

In Stock

Vaginal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Vaginal Cancer - Pipeline Review, H1 2016, provides an overview of the Vaginal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vaginal Cancer
- The report reviews pipeline therapeutics for Vaginal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vaginal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Vaginal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vaginal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vaginal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vaginal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vaginal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Vaginal Cancer - Overview 8
Vaginal Cancer - Therapeutics under Development by Companies 9
Vaginal Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Vaginal Cancer - Products under Development by Companies 11
Vaginal Cancer - Companies Involved in Therapeutics Development 12
ISA Pharmaceuticals B.V. 12
Nanotherapeutics, Inc. 13
Ono Pharmaceutical Co., Ltd. 14
Oryx GmbH & Co. KG 15
PDS Biotechnology Corporation 16
Taiwan Liposome Company, Ltd. 17
Vaginal Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ISA-101 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LN-145 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
nivolumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NTO-1151 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PDS-0101A - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TLC-388 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vicoryx - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Vaginal Cancer - Recent Pipeline Updates 45
Vaginal Cancer - Dormant Projects 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Vaginal Cancer, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Vaginal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 12
Vaginal Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016 13
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 14
Vaginal Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 15
Vaginal Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 16
Vaginal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Vaginal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 45
Vaginal Cancer - Dormant Projects, H1 2016 70

List of Figures
Number of Products under Development for Vaginal Cancer, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Targets, H1 2016 19
Number of Products by Stage and Targets, H1 2016 19
Number of Products by Mechanism of Actions, H1 2016 21
Number of Products by Stage and Mechanism of Actions, H1 2016 21
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25